MALTOMA
MCID: LYM104
MIFTS: 54

Lymphoma, Malt, Somatic (MALTOMA) malady

Categories: Genetic diseases, Blood diseases, Rare diseases, Cancer diseases, Immune diseases, Gastrointestinal diseases

Aliases & Classifications for Lymphoma, Malt, Somatic

Aliases & Descriptions for Lymphoma, Malt, Somatic:

Name: Lymphoma, Malt, Somatic 54 66 13 38
Malt Lymphoma 38 12 56 66 52 14
Mucosa-Associated Lymphoid Tissue Lymphoma 12 56 69
Lymphoma, Mucosa-Associated Lymphoid Type 54 66
Extranodal Marginal Zone B-Cell Lymphoma 56 69
Marginal Zone B-Cell Lymphoma 66 69
Gastric Lymphoma, Primary 66 52
Maltoma 56 66
Mucosa-Associated Lymphatic Tissue Lymphoma 56
Familial Primary Gastric Lymphoma 69
Lymphoma, B-Cell, Marginal Zone 42
Primary Gastric Lymphoma 66
Gastric Lymphoma 69

Characteristics:

Orphanet epidemiological data:

56
malt lymphoma
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/100000 (United States),1-9/100000 (Europe); Age of onset: Adult; Age of death: normal life expectancy;

Classifications:



External Ids:

OMIM 54 137245
Disease Ontology 12 DOID:0050909
Orphanet 56 ORPHA52417
ICD10 via Orphanet 34 C88.4
MedGen 40 C1850900
MeSH 42 D018442

Summaries for Lymphoma, Malt, Somatic

UniProtKB/Swiss-Prot : 66 Lymphoma, mucosa-associated lymphoid type: A subtype of non-Hodgkin lymphoma, originating in mucosa-associated lymphoid tissue. MALT lymphomas occur most commonly in the gastro- intestinal tract but have been described in a variety of extranodal sites including the ocular adnexa, salivary gland, thyroid, lung, thymus, and breast. Histologically, they are characterized by an infiltrate of small to medium-sized lymphocytes with abundant cytoplasm and irregularly shaped nuclei. Scattered transformed blasts (large cells) also are present. Non-malignant reactive follicles are observed frequently. A pivotal feature is the presence of lymphoepithelial lesions, with invasion and partial destruction of mucosal glands and crypts by aggregates of tumor cells.

MalaCards based summary : Lymphoma, Malt, Somatic, also known as malt lymphoma, is related to lymphoma and b-cell lymphomas, and has symptoms including constipation, fatigue and fever. An important gene associated with Lymphoma, Malt, Somatic is BCL10 (B-Cell CLL/Lymphoma 10), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Cyclophosphamide and Lenograstim have been mentioned in the context of this disorder. Affiliated tissues include b cells, thyroid and lung, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and hematopoietic system

Disease Ontology : 12 A non-Hodgkin lymphoma that has material basis in mucosal tissue involved in antibody production.

OMIM : 54 The concept of mucosa-associated lymphoid tissue (MALT) lymphomas was introduced by Isaacson and Wright (1983). MALT... (137245) more...

Related Diseases for Lymphoma, Malt, Somatic

Diseases related to Lymphoma, Malt, Somatic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 119)
id Related Disease Score Top Affiliating Genes
1 lymphoma 11.0
2 b-cell lymphomas 10.4
3 ichthyosis, congenital, autosomal recessive 10 10.3 BCL10 BCL6 IGH
4 pyloric antrum cancer 10.3 BCL10 BCL6 MALT1
5 prader-willi syndrome due to translocation 10.3 BCL6 CXCR5
6 diffuse large b-cell lymphoma 10.3
7 trigeminal nerve neoplasm 10.3 CD5 MME
8 teebi naguib al awadi syndrome 10.3 BCL6 IGH MME
9 coloboma of eyelid 10.2 BCL6 CD5 MME
10 rubella panencephalitis 10.2 BCL6 MALT1
11 thyroiditis 10.2
12 parotitis 10.2 BIRC3 CCND1 CD5 MALT1
13 basal ganglia disease 10.2 BCL6 CD5 MALT1
14 marginal zone b-cell lymphoma 10.2
15 childhood brain stem glioma 10.2 CCND1 CD5 MME
16 prader-willi syndrome due to paternal deletion of 15q11q13 type 1 10.2 BCL10 MALT1
17 brca1 and brca2 hereditary breast and ovarian cancer 10.2 BCL10 BCL6 BIRC3 CXCR3 MALT1
18 tall cell variant papillary carcinoma 10.2 BCL6 CD40 MME
19 hyperphosphatasia with mental retardation syndrome 2 10.2 FOXP1 IGH MME
20 adenocarcinoma 10.1
21 ethmoid sinus inverted papilloma 10.1 BCL6 MME
22 ritscher-schinzel syndrome 10.1 BCL6 CD40 CXCL13 CXCR5
23 melanoma metastasis 10.1 BCL6 CCND1 CD40 CD5 IGH MME
24 b-cell lymphoma of mucosa-associated lymphoid tissue 10.1
25 microcystic adenoma 10.0 BCL10 BCL6 BIRC3 CCND1 CD5 MALT1
26 gingival recession 10.0 BCL6 CCND1 CD40 CXCR5 IGH MME
27 gastritis 10.0
28 gastric adenocarcinoma 10.0
29 hepatitis 10.0
30 chlamydia 10.0
31 ectodermal dysplasia 10.0 BCL10 BCL6 CARD11 CCND1 CD5 FOXP1
32 marantic endocarditis 10.0 BCL10 BCL6 CARD11 CCND1 CXCL13 CXCR5
33 duodenitis 10.0
34 mucositis 10.0
35 gastric cancer 10.0
36 follicular lymphoma 9.9
37 mantle cell lymphoma 9.9
38 bladder disease 9.9 BCL10 BCL6 BIRC3 CARD11 CCND1 CD40
39 chronic venous leg ulcers 9.9 BCL10 BCL6 BIRC3 CCND1 CD40 CD5
40 plasmacytoma 9.8
41 lupus erythematosus 9.8
42 systemic lupus erythematosus 9.8
43 macroglobulinemia 9.8
44 hodgkin lymphoma 9.8
45 pulmonary fibrosis, idiopathic 9.8 BCL10 BCL6 BIRC3 CCND1 CD40 CD5
46 sjogren's syndrome 9.8
47 ulcerative colitis 9.8
48 histiocytosis 9.8
49 ataxia 9.8
50 arthritis 9.8

Graphical network of the top 20 diseases related to Lymphoma, Malt, Somatic:



Diseases related to Lymphoma, Malt, Somatic

Symptoms & Phenotypes for Lymphoma, Malt, Somatic

Clinical features from OMIM:

137245

Human phenotypes related to Lymphoma, Malt, Somatic:

56 32 (show all 18)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 constipation 56 32 Frequent (79-30%) HP:0002019
2 fatigue 56 32 Very frequent (99-80%) HP:0012378
3 fever 56 32 Very frequent (99-80%) HP:0001945
4 abdominal pain 56 32 Occasional (29-5%) HP:0002027
5 nausea and vomiting 56 32 Very frequent (99-80%) HP:0002017
6 hyperhidrosis 56 32 Very frequent (99-80%) HP:0000975
7 recurrent respiratory infections 56 32 Occasional (29-5%) HP:0002205
8 visual impairment 56 32 Occasional (29-5%) HP:0000505
9 anemia 56 32 Very frequent (99-80%) HP:0001903
10 weight loss 56 32 Very frequent (99-80%) HP:0001824
11 mediastinal lymphadenopathy 56 32 Occasional (29-5%) HP:0100721
12 abnormality of the thyroid gland 56 32 Occasional (29-5%) HP:0000820
13 pulmonary infiltrates 56 32 Very frequent (99-80%) HP:0002113
14 abnormality of the nasolacrimal system 56 32 Occasional (29-5%) HP:0000614
15 b-cell lymphoma 56 32 Very frequent (99-80%) HP:0012191
16 posterior uveitis 56 32 Occasional (29-5%) HP:0012123
17 lymphadenopathy 56 Occasional (29-5%)
18 gastric lymphoma 32 HP:0045038

GenomeRNAi Phenotypes related to Lymphoma, Malt, Somatic according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.47 BCL10 BIRC2 BIRC3 CARD11 DUSP5 MALT1
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.47 BCL10 BIRC2 BIRC3 CARD11 CCND1 CD40

MGI Mouse Phenotypes related to Lymphoma, Malt, Somatic:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.77 BCL10 BCL6 BIRC2 BIRC3 CARD11 CCND1
2 immune system MP:0005387 9.47 BCL10 BCL6 BIRC2 BIRC3 CARD11 CCND1

Drugs & Therapeutics for Lymphoma, Malt, Somatic

Drugs for Lymphoma, Malt, Somatic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 482)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
2
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 135968-09-1
3
Thiotepa Approved Phase 4,Phase 2,Phase 3 52-24-4 5453
4
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Phase 2 26787-78-0 33613 2171
5
Clarithromycin Approved Phase 4,Phase 3,Phase 2 81103-11-9 84029
6
Metronidazole Approved Phase 4,Phase 3,Phase 2 443-48-1 4173
7
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2 564-25-0 54671203
8
Esomeprazole Approved, Investigational Phase 4,Phase 2 161796-78-7, 119141-88-7 4594 9579578
9 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
10 Antilymphocyte Serum Phase 4,Phase 2,Phase 3,Phase 1
11 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
12 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
13 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
14 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
15 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
16 Antiparasitic Agents Phase 4,Phase 3,Phase 2,Phase 1
17 Antiprotozoal Agents Phase 4,Phase 3,Phase 2,Phase 1
18 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
19 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
20 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
21
Proton pump inhibitors Phase 4,Phase 3,Phase 2
22 Antacids Phase 4,Phase 2
23 Anti-Ulcer Agents Phase 4,Phase 2
24 Antimalarials Phase 4,Phase 2,Phase 1
25
Fludarabine Approved Phase 3,Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
26
rituximab Approved Phase 3,Phase 2,Phase 1,Early Phase 1 174722-31-7 10201696
27
Vidarabine Approved Phase 3,Phase 1,Phase 2 24356-66-9 32326 21704
28
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
29
Doxorubicin Approved, Investigational Phase 3,Phase 1,Phase 2 23214-92-8 31703
30
Prednisone Approved, Vet_approved Phase 3,Phase 2,Phase 1 53-03-2 5865
31
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
32
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 55-98-1 2478
33
Idarubicin Approved Phase 3 58957-92-9 42890
34
Melphalan Approved Phase 3,Phase 2,Phase 1 148-82-3 4053 460612
35
Iron Approved Phase 3,Phase 1,Phase 2 7439-89-6 23925
36
Chlorambucil Approved Phase 3,Phase 2 305-03-3 2708
37
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
38
Cefepime Approved Phase 3,Phase 1 88040-23-7 5479537
39
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
40
Ofloxacin Approved Phase 3 82419-36-1 4583
41
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
42
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
43
Cyclosporine Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 79217-60-0, 59865-13-3 5284373 6435893
44
Lenalidomide Approved Phase 3,Phase 2,Phase 1 191732-72-6 216326
45
Carboplatin Approved Phase 2, Phase 3,Phase 1 41575-94-4 10339178 498142 38904
46
Etoposide Approved Phase 2, Phase 3,Phase 1,Early Phase 1 33419-42-0 36462
47
Mycophenolate mofetil Approved, Investigational Phase 3,Phase 2,Phase 1 128794-94-5 5281078
48
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1 24280-93-1 446541
49
Methotrexate Approved Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
50
Piperacillin Approved Phase 3 66258-76-2 43672

Interventional clinical trials:

(show top 50) (show all 686)
id Name Status NCT ID Phase
1 Lymphoma in the Orbit Unknown status NCT01302912 Phase 4
2 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4
3 10-day Versus 14-day Concomitant PAMC as First-line Treatment Strategy for the Eradication of H. Pylori Infection Not yet recruiting NCT02959255 Phase 4
4 High Dose Dual Therapy (HDDT) for Eradication of Helicobacter Pylori Infection Not yet recruiting NCT02553083 Phase 4
5 Helicobacter – Lymphoma – Radiation Part I: Eradication, Part II: Radiation Unknown status NCT00154440 Phase 3
6 Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
7 Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
8 Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma Unknown status NCT00551239 Phase 3
9 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3
10 Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3
11 Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome Unknown status NCT00002989 Phase 3
12 Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer Unknown status NCT00482716 Phase 3
13 Combination Chemotherapy With or Without Interferon Alfa in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma Unknown status NCT00003639 Phase 3
14 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3
15 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3
16 Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma Unknown status NCT00003924 Phase 3
17 Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia Completed NCT00566332 Phase 3
18 A Phase Ⅲ Clinical Trial With Oral Recombinant Helicobacter Pylori Vaccine in Chinese Children Completed NCT02302170 Phase 3
19 Bendamustine Plus Rituximab Versus CHOP Plus Rituximab Completed NCT00991211 Phase 3
20 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
21 Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma Completed NCT00278408 Phase 3
22 Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma Completed NCT00278421 Phase 3
23 Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy Completed NCT00003341 Phase 3
24 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3
25 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
26 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3
27 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
28 Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count Completed NCT00003805 Phase 3
29 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
30 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3
31 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3
32 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3
33 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3
34 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
35 Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer Completed NCT00265837 Phase 3
36 Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma Completed NCT00004112 Phase 3
37 Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation Completed NCT00014391 Phase 3
38 Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation Completed NCT00003883 Phase 3
39 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
40 Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation Completed NCT00004230 Phase 3
41 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3
42 Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer Completed NCT00053053 Phase 3
43 Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases Completed NCT00438958 Phase 3
44 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3
45 Chlorambucil or Fludarabine as First-Line Therapy in Treating Patients With Previously Untreated Waldenström Macroglobulinemia, Splenic Lymphoma, or Lymphoplasmacytic Lymphoma Completed NCT00608374 Phase 3
46 Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder Completed NCT00755040 Phase 3
47 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3
48 Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin's Disease Completed NCT00003414 Phase 3
49 Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma. Recruiting NCT01996865 Phase 3
50 Safety and Efficacy Study of BCD-020 in Therapy of Non-Hodgkin's Lymphoma Recruiting NCT01701232 Phase 3

Search NIH Clinical Center for Lymphoma, Malt, Somatic

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Lymphoma, Malt, Somatic cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Lymphoma, Malt, Somatic:
Hematopoietic stem cells for treatment of hematologic malignancies
Embryonic/Adult Cultured Cells Related to Lymphoma, Malt, Somatic:
Bone marrow-derived hematopoietic stem cells

Cochrane evidence based reviews: lymphoma, b-cell, marginal zone

Genetic Tests for Lymphoma, Malt, Somatic

Anatomical Context for Lymphoma, Malt, Somatic

MalaCards organs/tissues related to Lymphoma, Malt, Somatic:

39
B Cells, Thyroid, Lung, Breast, Thymus, Salivary Gland, Bone

Publications for Lymphoma, Malt, Somatic

Variations for Lymphoma, Malt, Somatic

Cosmic variations for Lymphoma, Malt, Somatic:

9
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM36072 NOTCH2 haematopoietic and lymphoid tissue,extranodal,lymphoid neoplasm,MALT lymphoma c.4912C>T p.H1638Y 11
2 COSM85940 MYD88 haematopoietic and lymphoid tissue,extranodal,lymphoid neoplasm,MALT lymphoma c.794T>C p.L265P 11
3 COSM303679 TNFAIP3 haematopoietic and lymphoid tissue,ocular adnexa,lymphoid neoplasm,MALT lymphoma c.581T>C p.I194T 9
4 COSM35925 TNFAIP3 haematopoietic and lymphoid tissue,ocular adnexa,lymphoid neoplasm,MALT lymphoma c.1004T>G p.L335* 9
5 COSM303694 TNFAIP3 haematopoietic and lymphoid tissue,ocular adnexa,lymphoid neoplasm,MALT lymphoma c.1485T>A p.C495* 9
6 COSM303677 TNFAIP3 haematopoietic and lymphoid tissue,ocular adnexa,lymphoid neoplasm,MALT lymphoma c.1367G>T p.G456V 9
7 COSM303674 TNFAIP3 haematopoietic and lymphoid tissue,ocular adnexa,lymphoid neoplasm,MALT lymphoma c.1282G>T p.E428* 9
8 COSM303675 TNFAIP3 haematopoietic and lymphoid tissue,ocular adnexa,lymphoid neoplasm,MALT lymphoma c.1507C>T p.Q503* 9
9 COSM303671 TNFAIP3 haematopoietic and lymphoid tissue,ocular adnexa,lymphoid neoplasm,MALT lymphoma c.733A>T p.R245* 9

Copy number variations for Lymphoma, Malt, Somatic from CNVD:

7
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 119732 18 16100000 76117153 Gain MALT1 Mucosa-associated lymphoid tissue lymphomas
2 206010 6 135101251 139048099 Loss TNFAIP3 Mucosa-associated lymphoid tissue lymphomas

Expression for Lymphoma, Malt, Somatic

Search GEO for disease gene expression data for Lymphoma, Malt, Somatic.

Pathways for Lymphoma, Malt, Somatic

Pathways related to Lymphoma, Malt, Somatic according to GeneCards Suite gene sharing:

(show all 20)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.86 BCL10 BCL6 BIRC2 BIRC3 CARD11 CCND1
2
Show member pathways
13.23 BCL6 BIRC2 BIRC3 CCND1 CD40 DUSP5
3
Show member pathways
12.69 CCND1 CD40 CXCL13 CXCR5 HSPD1 MADCAM1
4
Show member pathways
12.55 BCL10 CARD11 CD40 MALT1 TRAF2
5
Show member pathways
12.47 BCL10 CARD11 CD40 IGH MALT1
6 12.39 BCL10 BCL6 CARD11 MALT1 TRAF2
7
Show member pathways
12.24 BCL10 CARD11 CD40 MALT1
8
Show member pathways
12.22 BCL10 BCL6 CARD11 MALT1
9 11.98 BCL10 BIRC2 BIRC3 MALT1 TRAF2
10
Show member pathways
11.8 BCL10 CARD11 MALT1
11 11.79 BIRC2 BIRC3 TRAF2
12
Show member pathways
11.66 BIRC2 CXCL13 TRAF2
13 11.63 BIRC2 BIRC3 CCND1 TRAF2
14
Show member pathways
11.53 BIRC2 BIRC3 CD40 TRAF2
15
Show member pathways
11.5 BIRC2 BIRC3 CCND1
16 11.4 BCL6 CD40 CXCL13 CXCR5 MADCAM1
17 11.15 BCL10 BIRC2 BIRC3 CARD11 CD40 MALT1
18 11.08 BCL6 CD40 CD5 CXCR5 MME
19 11.03 BIRC2 BIRC3 CD40 TRAF2
20 10.97 BCL10 BIRC2 MALT1

GO Terms for Lymphoma, Malt, Somatic

Cellular components related to Lymphoma, Malt, Somatic according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein complex GO:0043234 9.73 BCL10 BIRC2 BIRC3 HSPD1 MALT1 TRAF2
2 external side of plasma membrane GO:0009897 9.67 CD40 CD5 CXCR3 CXCR5
3 T cell receptor complex GO:0042101 9.4 BCL10 CARD11
4 lipopolysaccharide receptor complex GO:0046696 9.32 BCL10 HSPD1
5 CBM complex GO:0032449 9.16 BCL10 MALT1
6 CD40 receptor complex GO:0035631 9.13 BIRC2 CD40 TRAF2
7 membrane raft GO:0045121 9.1 BCL10 BIRC2 BIRC3 CARD11 HSPD1 TRAF2

Biological processes related to Lymphoma, Malt, Somatic according to GeneCards Suite gene sharing:

(show all 42)
id Name GO ID Score Top Affiliating Genes
1 cell surface receptor signaling pathway GO:0007166 9.98 BIRC2 BIRC3 CXCL13 CXCR3
2 regulation of cell proliferation GO:0042127 9.96 BCL6 BIRC2 CD40 CXCL13
3 regulation of immune response GO:0050776 9.94 BCL6 CARD11 CD40 MADCAM1
4 chemotaxis GO:0006935 9.89 CXCL13 CXCR3 CXCR5 S100A8
5 response to lipopolysaccharide GO:0032496 9.88 CD40 CXCL13 FOXP1 HSPD1 S100A8
6 tumor necrosis factor-mediated signaling pathway GO:0033209 9.86 BIRC2 BIRC3 CD40 TRAF2
7 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.84 HSPD1 S100A8 TRAF2
8 chemokine-mediated signaling pathway GO:0070098 9.82 CXCL13 CXCR3 CXCR5
9 positive regulation of protein ubiquitination GO:0031398 9.8 BCL10 BIRC3 MALT1
10 protein heterooligomerization GO:0051291 9.76 BCL10 BIRC2 BIRC3 TRAF2
11 positive regulation of B cell proliferation GO:0030890 9.74 BCL6 CARD11 CD40
12 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.73 BCL10 BIRC2 BIRC3 TRAF2
13 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.73 BCL10 CARD11 CD40 MALT1 S100A8 TRAF2
14 B cell proliferation GO:0042100 9.72 CARD11 CD40 HSPD1
15 regulation of inflammatory response GO:0050727 9.72 BCL6 BIRC2 BIRC3 FOXP1 S100A8
16 regulation of apoptotic process GO:0042981 9.7 BCL10 BCL6 BIRC2 BIRC3 CARD11 MALT1
17 activation of NF-kappaB-inducing kinase activity GO:0007250 9.69 MALT1 TRAF2
18 regulation of tumor necrosis factor-mediated signaling pathway GO:0010803 9.69 BIRC2 BIRC3 TRAF2
19 lymph node development GO:0048535 9.68 CXCL13 CXCR5
20 positive regulation of interleukin-2 production GO:0032743 9.68 MALT1 TRAF2
21 regulation of innate immune response GO:0045088 9.68 BIRC2 BIRC3
22 response to molecule of bacterial origin GO:0002237 9.67 BCL10 MALT1
23 B cell activation GO:0042113 9.67 CD40 CXCR5 HSPD1 MALT1
24 inhibition of cysteine-type endopeptidase activity involved in apoptotic process GO:1990001 9.66 BIRC2 BIRC3
25 chronic inflammatory response GO:0002544 9.65 CXCL13 S100A8
26 negative regulation of necroptotic process GO:0060546 9.65 BIRC2 BIRC3
27 positive regulation of T cell cytokine production GO:0002726 9.64 MALT1 TRAF2
28 germinal center formation GO:0002467 9.63 BCL6 CXCL13
29 negative regulation of B cell apoptotic process GO:0002903 9.63 BCL6 FOXP1
30 response to fungus GO:0009620 9.61 BCL10 MALT1
31 regulation of T cell receptor signaling pathway GO:0050856 9.6 BCL10 MALT1
32 regulation of immunoglobulin secretion GO:0051023 9.58 CD40 TRAF2
33 regulation of toll-like receptor signaling pathway GO:0034121 9.58 BIRC2 BIRC3
34 regulation of necroptotic process GO:0060544 9.58 BIRC2 BIRC3 TRAF2
35 regulation of cysteine-type endopeptidase activity GO:2000116 9.54 BIRC2 BIRC3
36 regulation of nucleotide-binding oligomerization domain containing signaling pathway GO:0070424 9.52 BIRC2 BIRC3
37 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.5 BCL10 BIRC2 BIRC3 CARD11 CD40 MALT1
38 regulation of RIG-I signaling pathway GO:0039535 9.49 BIRC2 BIRC3
39 positive regulation of T cell activation GO:0050870 9.02 BCL10 CARD11 HSPD1 MALT1 TRAF2
40 apoptotic process GO:0006915 10.09 BCL10 BIRC2 BIRC3 CXCR3 S100A8 TRAF2
41 negative regulation of apoptotic process GO:0043066 10.07 BCL6 BIRC2 BIRC3 HSPD1 MALT1
42 inflammatory response GO:0006954 10 BCL6 CD40 CXCL13 CXCR3 S100A8

Molecular functions related to Lymphoma, Malt, Somatic according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 ubiquitin protein ligase binding GO:0031625 9.67 BCL10 CD40 HSPD1 TRAF2
2 protease binding GO:0002020 9.5 BCL10 HSPD1 MALT1
3 C-X-C chemokine receptor activity GO:0016494 9.26 CXCR3 CXCR5
4 kinase activator activity GO:0019209 9.16 BCL10 MALT1
5 protein self-association GO:0043621 9.13 BCL10 FOXP1 MALT1
6 enzyme binding GO:0019899 9.02 BCL10 CCND1 CD40 HSPD1 TRAF2

Sources for Lymphoma, Malt, Somatic

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....